Quick Answer
Relay Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $84.02 million for the year ending 2025.
- Relay Therapeutics, Inc. showed a decrease of -32.4% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Relay Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2019: $39.36 million | Q3 2019: $29.05 million | Q1 2020: $70.34 million | Q2 2020: $137.05 million | Q3 2020: $559.28 million | Q1 2021: $262.72 million | Q2 2021: $260.07 million | Q3 2021: $228.56 million | Q1 2022: $119.45 million | Q2 2022: $107.74 million | Q3 2022: $354.64 million | Q1 2023: $161.28 million | Q2 2023: $145.90 million | Q3 2023: $151.33 million | Q1 2024: $152.87 million | Q2 2024: $134.13 million | Q3 2024: $152.36 million | Q1 2025: $93.54 million | Q2 2025: $113.94 million | Q3 2025: $91.56 million.
- Over the full 7 years of available data (2019 to 2025), Relay Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 100.3%.
- Historical annual values: Fiscal year 2025: $84.02 million | Fiscal year 2024: $124.29 million | Fiscal year 2023: $143.74 million | Fiscal year 2022: $151.79 million | Fiscal year 2021: $280.12 million | Fiscal year 2020: $447.65 million | Fiscal year 2019: $41.95 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: